Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 5, 2008, Pages 405-409

  Sidelmann, Johannes J ^a   Bladbjerg, Else Marie ^a   Gram, Jørgen ^a   Münster, Anna Marie B ^a   Jespersen, Jørgen ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

C reactive protein; D Dimer; Deep venous thrombosis; Tissue factor pathway inhibitor; Von Willebrand Factor

Indexed keywords

C REACTIVE PROTEIN; D DIMER; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

ACUTE DISEASE; ADULT; ARTICLE; BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONFOUNDING VARIABLE; DEEP VEIN THROMBOSIS; ENDOTHELIUM CELL; FEMALE; FIBRIN DEPOSITION; FIBRINOLYSIS; GENETIC POLYMORPHISM; GENOTYPE; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PHLEBOGRAPHY; PRIORITY JOURNAL;

ACUTE DISEASE; C-REACTIVE PROTEIN; ENDOTHELIAL CELLS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GENOTYPE; HUMANS; INFLAMMATION; LIPOPROTEINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; VENOUS THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 67649532175     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283049639     Document Type: Article

References (34)

1. Sidelmann JJ, Gram J, Jespersen J, Kluft C. Fibrin clot formation and lysis: basic mechanisms. Semin Thromb Hemost 2000; 26:605-618.
2. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86:959-972.
3. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006; 208:327-339.
4. Maroney SA, Haberichter SL, Friese P,Collins ML, Ferrel JP, Dale GL, Mast AE. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood 2007; 109:1931-1937.
5. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol 2002; 22:539-548.
6. Bladbjerg EM, Madsen JS, Kristensen SR, Abrahamsen B, Brixen K, Mosekilde L, Jespersen J. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 2003; 1:1208-1214.
7. Ornberg RL, Deune EG, Ozbek MR, Wun TC, Khouri RK. Localization of topically applied TFPI binding sites in an intimectomized microvessel. Thromb Haemost 1995; 73:55-58.
8. Ohkura N, Enjyoji K, Kamikubo Y, Kato H. A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin. Blood 1997; 90:1883-1892.
9. Ameziane N, Seguin C, Borgel D, Fumeron F, Moatti D, Alhenc-Gelas M, et al. The -33T->C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations. Thromb Haemost 2002; 88:195-199.
10. Moatti D, Meirhaeghe A, Ollivier V, Bauters C, Amouyel P, de Prost D. Polymorphisms of the tissue factor pathway inhibitor gene and the risk of restenosis after coronary angioplasty. Blood Coagul Fibrinolysis 2001; 12:317-323.
11. Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, Grant PJ, Ariens RA. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2001; 113:537-543.
12. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, et al. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004; 109:1343-1348.
13. Hoke M, Kyrle PA, Minar E, Bialonzcyk C, Hirschl M, Schneider B, et al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost 2005; 94:787-790.
14. Dahm A, Van Hylckama Vlieq A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101:4387-4392.
15. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998; 79:495-499.
16. Kim HK, Song KS, Park YS, Yun YS, Shim WH. Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease. Cardiology 2000; 93:31-36.
17. Maly M, Vojacek J, Hrabos V, Kvasnicka J, Salaj P, Durdil V. Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndrome. Physiol Res 2003; 52:719-728.
18. Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiku H, et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol 1997; 55:183-187.
19. Takahashi H, Sato N, Shibata A. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: comparison of its behavior with plasma tissue factor. Thromb Res 1995; 80:339-348.
20. Sidelmann JJ, Sjoland JA, Gram J, Bertelsen V, Mourits-Andersen T, Munster H, et al. Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis. Scand J Clin Lab Invest 2007; 67:270-279.
21. Rabinov K, Paulin S. Dynamics of venous contrast filling in the normal venogram. In: Abrams HL, editor. Abrams angiography. Vascular and interventional radiology. Boston: Little, Brown and Co.; 1983. pp. 1884- 1887.
22. Bladbjerg EM, Gram J, Jespersen J, de Maat MP. Internal quality control of PCR-based genotyping methods in research studies and patient diagnostics. Thromb Haemost 2002; 87:812-816.
23. Freeburn JC, Wallace JM, Strain JJ, Sinnamon DG, Craig BM, Johnson D, Gilmore WS. Monocyte tissue factor-like activity in post myocardial infarction patients. Br J Haematol 1998; 102:605-608.
24. Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Morishita E, et al. Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases. Blood Coagul Fibrinolysis 2001; 12:1-8.
25. Hamuro T, Kido H, Asada Y, Hatakeyama K, Okumura Y, Kunori Y, et al. Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis. FEBS J 2007; 274:3065-3077.
26. Souto JC, Martinez E, Roca M, Mateo J, Pujol J, Gonzalez D, Fontcuberta J. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40:1883-1889.
27. Berrettini M, Malaspina M, Parise P, Lucarelli G, Kisiel W, Nenci GG. A simple chromogenic substrate assay of tissue factor pathway inhibitor activity in plasma and serum. Am J Clin Pathol 1995; 103:391-395.
28. Roumen-Klappe EM, den Heijer M, van Uum SH, van der Ven-Jorgekrijg J, van der Graaf F, Wollersheim H. Inflammatory response in the acute phase of deep vein thrombosis. J Vasc Surg 2002; 35:701-706.
29. Bucek RA, Reiter M, Quehenberger P, Weltermann A, Kyrle PA, Minar E. Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters? Br J Haematol 2003; 120:123-128.
30. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005; 94:362-365.
31. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006; 95:49-55.
32. Jennersjo CM, Fagerberg IH, Karlander SG, Lindahl TL. Normal D-dimer concentration is a common finding in symptomatic outpatients with distal deep vein thrombosis. Blood Coagul Fibrinolysis 2005; 16:517-523.
33. Wuillemin WA, Korte W, Waser G, Lammle B. Usefulness of the D-dimer/ fibrinogen ratio to predict deep venous thrombosis. J Thromb Haemost 2005; 3:385-387.
34. Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S, et al. Measurement of the clinical and cost-effectiveness of noninvasive diagnostic testing strategies for deep vein thrombosis. Health Technol Assess 2006; 10:1-168.